Evidence map›Paper›PMID 29721809›Full record

ArticleJournal of bone and mineral metabolism2019

Gushukang exerts osteopreserve effects by regulating vitamin D and calcium metabolism in ovariectomized mice.

Xiao-Li Li, Liang Wang, Xiao-Lei Bi, Bing-Bing Chen, Yan Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of bone and mineral metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Qing`e Pill Inhibits Osteoblast FerroptosisFrontiers in pharmacology · 2022
    Article
  6. Article
  7. Article
  8. Positive Effect of Gushukang on Type-H Vessel and Bone Formation.Frontiers in cell and developmental biology · 2020
    Article
  9. miR-193-3p ameliorates bone resorption in ovariectomized mice by blocking NFATc1 signaling.International journal of clinical and experimental pathology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Xiao-Li LiSchool of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, People's Republic of China.
Liang WangDepartment of Orthopaedics, The 309th Hospital of Chinese People's Liberation Army, Beijing, 100091, People's Republic of China.
Xiao-Lei BiLiaoning Konruns Pharmaceutical Co., Ltd, Dandong, 118301, People's Republic of China.
Bing-Bing ChenSchool of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, 200093, People's Republic of China.
Yan ZhangSpine Disease Research Institute, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Room 908, Building #12, South Wanping Road 725, Shanghai, 200032, People's Republic of China. medicineyan@163.com.
University of Shanghai for Science and Technology · CNLianyungang Runzhong Pharmaceutical (China) · CNShanghai University of Traditional Chinese Medicine · CNThe 309th Hospital of Chinese People's Liberation Army · CN

Funding

National Natural Science Foundation of China 81774329Natural Science Foundation of Shanghai 17ZR1430800
6 · The paper itself

Abstract

Calcium homeostasis plays vital roles in the management of bone health. Traditional herbal formula Gushukang (GSK) was clinically applied to treat primary osteoporosis. This study aimed to explore the osteoprotective effects of GSK and its roles in maintaining calcium homeostasis in ovariectomized (OVX) mice. The OVX mice were orally treated with low (0.38 g/kg), middle (0.76 g/kg) and high (1.52 g/kg) dose of GSK for 8 weeks. GSK treatment dramatically increased serum calcium level and decreased urinary calcium excretion as well as enhanced calcium content in bone of OVX mice. Serum level of 25-hydroxyvitamin D was significantly increased in OVX mice with exposure to GSK. Treatment with GSK improved bone mass and micro-structure of trabecular bone at distal metaphysis of femur and proximal metaphysis of tibia in OVX mice shown by safranin O staining and micro-CT measurement. GSK treatment at all doses up-regulated mRNA expression of calcium-binding protein-28k and vitamin D receptor in kidney of OVX mice, and dose-dependently decreased mRNA expression of claudin-14 and elevated mRNA expression of claudin-16 in duodenum of OVX mice. Taken together, GSK exerted beneficial effects on trabecular bone of OVX mice by improving calcium homeostasis via regulating paracellular calcium absorption in duodenum and transcellular calcium reabsorption in kidney.

Indexed as

OvariectomyAnimalsBody WeightBone Density Conservation AgentsCalciumClaudinsDrugs, Chinese HerbalFemaleFemurGene Expression RegulationIntestinal AbsorptionMice, Inbred C57BLRNA, MessengerTibiaUterusVitamin D25-hydroxyvitamin DBone Density Conservation AgentsCalciumClaudinsDrugs, Chinese HerbalgushukangRNA, MessengerVitamin DCalcium transportDuodenumGushukangKidneyOsteoporosis

Identifiers

PMID29721809
OpenAlexW2802365750

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.